{"entity":{"type":"insider","cik":"0001493811","url":"/insider/0001493811","json_url":"/insider/0001493811.json","name":"Weyer Christian","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":15,"first":"2010-11-19","last":"2020-04-29","span_basis":"filed_date"},"name_variants":[{"name":"Weyer Christian","source":"filing","n_filings":15,"first_seen":"2010-11-19","last_seen":"2020-04-29"}],"transactions":[{"id":2557247,"accession":"0001104659-20-053658","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-053658","line_url":"/filing/0001104659-20-053658#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":181.0,"shares_display":"181","price_per_share":85.95,"price_display":"85.95","price_state":"stated","total_value":15556.95,"total_display":"15,556.95","total_whole":"15,557","shares_owned_after":17140.0,"shares_owned_after_display":"17,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-27","filed_date":"2020-04-29","scope":"insider"},{"id":2957856,"accession":"0001104659-20-027330","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-027330","line_url":"/filing/0001104659-20-027330#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":113.0,"shares_display":"113","price_per_share":87.62,"price_display":"87.62","price_state":"stated","total_value":9901.06,"total_display":"9,901.06","total_whole":"9,901","shares_owned_after":17367.0,"shares_owned_after_display":"17,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-27","filed_date":"2020-02-28","scope":"insider"},{"id":2790003,"accession":"0001104659-20-007260","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-007260","line_url":"/filing/0001104659-20-007260#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":723.0,"shares_display":"723","price_per_share":94.04,"price_display":"94.04","price_state":"stated","total_value":67990.92,"total_display":"67,990.92","total_whole":"67,991","shares_owned_after":17837.0,"shares_owned_after_display":"17,837","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-27","filed_date":"2020-01-27","scope":"insider"},{"id":8237995,"accession":"0001104659-19-076864","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-19-076864","line_url":"/filing/0001104659-19-076864#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1581.0,"shares_display":"1,581","price_per_share":123.24,"price_display":"123.24","price_state":"stated","total_value":194842.44,"total_display":"194,842.44","total_whole":"194,842","shares_owned_after":14178.0,"shares_owned_after_display":"14,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-27","filed_date":"2019-12-30","scope":"insider"},{"id":8054236,"accession":"0001104659-19-069103","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-19-069103","line_url":"/filing/0001104659-19-069103#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1040.0,"shares_display":"1,040","price_per_share":101.65,"price_display":"101.65","price_state":"stated","total_value":105716.0,"total_display":"105,716.00","total_whole":"105,716","shares_owned_after":15646.0,"shares_owned_after_display":"15,646","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-27","filed_date":"2019-12-02","scope":"insider"},{"id":8699257,"accession":"0001104659-19-068398","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-19-068398","line_url":"/filing/0001104659-19-068398#line-6","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4373.0,"shares_display":"4,373","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":437300.0,"total_display":"437,300.00","total_whole":"437,300","shares_owned_after":15759.0,"shares_owned_after_display":"15,759","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-26","filed_date":"2019-11-27","scope":"insider"},{"id":8699249,"accession":"0001104659-19-068398","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-19-068398","line_url":"/filing/0001104659-19-068398#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1855.0,"shares_display":"1,855","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":185500.0,"total_display":"185,500.00","total_whole":"185,500","shares_owned_after":15759.0,"shares_owned_after_display":"15,759","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-11-27","scope":"insider"},{"id":7912987,"accession":"0001104659-19-065555","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-065555","line_url":"/filing/0001104659-19-065555#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1550.0,"shares_display":"1,550","price_per_share":85.0,"price_display":"85.00","price_state":"stated","total_value":131750.0,"total_display":"131,750.00","total_whole":"131,750","shares_owned_after":15759.0,"shares_owned_after_display":"15,759","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-19","filed_date":"2019-11-19","scope":"insider"},{"id":8054213,"accession":"0001104659-19-064831","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-064831","line_url":"/filing/0001104659-19-064831#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":946.0,"shares_display":"946","price_per_share":85.0,"price_display":"85.00","price_state":"stated","total_value":80410.0,"total_display":"80,410.00","total_whole":"80,410","shares_owned_after":17309.0,"shares_owned_after_display":"17,309","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-11-13","filed_date":"2019-11-15","scope":"insider"},{"id":8385925,"accession":"0001144204-19-011720","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-011720","line_url":"/filing/0001144204-19-011720#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":333.0,"shares_display":"333","price_per_share":103.16,"price_display":"103.16","price_state":"stated","total_value":34352.28,"total_display":"34,352.28","total_whole":"34,352","shares_owned_after":19107.0,"shares_owned_after_display":"19,107","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-01","filed_date":"2019-03-01","scope":"insider"},{"id":6593940,"accession":"0001144204-18-062413","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-18-062413","line_url":"/filing/0001144204-18-062413#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS, INC.","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1343.0,"shares_display":"1,343","price_per_share":113.78,"price_display":"113.78","price_state":"stated","total_value":152806.54,"total_display":"152,806.54","total_whole":"152,807","shares_owned_after":15819.0,"shares_owned_after_display":"15,819","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-29","filed_date":"2018-11-29","scope":"insider"},{"id":6921415,"accession":"0001493811-14-000002","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001493811-14-000002","line_url":"/filing/0001493811-14-000002#line-4","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2262.0,"shares_display":"2,262","price_per_share":9.0164,"price_display":"9.02","price_state":"stated","total_value":20395.0968,"total_display":"20,395.10","total_whole":"20,395","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-04-02","filed_date":"2014-04-03","scope":"insider"},{"id":6921411,"accession":"0001493811-14-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493811-14-000002","line_url":"/filing/0001493811-14-000002#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7738.0,"shares_display":"7,738","price_per_share":9.019,"price_display":"9.02","price_state":"stated","total_value":69789.022,"total_display":"69,789.02","total_whole":"69,789","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-04-01","filed_date":"2014-04-03","scope":"insider"},{"id":3504583,"accession":"0001264124-12-000084","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001264124-12-000084","line_url":"/filing/0001264124-12-000084#line-1","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (SVP, Research & Development), Other","role_mark":"O","role_mark_label":"Officer (SVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1231.0,"shares_display":"1,231","price_per_share":17.11,"price_display":"17.11","price_state":"stated","total_value":21062.41,"total_display":"21,062.41","total_whole":"21,062","shares_owned_after":24167.6,"shares_owned_after_display":"24,167.60","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-01","filed_date":"2012-03-02","scope":"insider"},{"id":3244259,"accession":"0001264124-12-000064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001264124-12-000064","line_url":"/filing/0001264124-12-000064#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (SVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (SVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2519.0,"shares_display":"2,519","price_per_share":17.0302,"price_display":"17.03","price_state":"stated","total_value":42899.0738,"total_display":"42,899.07","total_whole":"42,899","shares_owned_after":24596.6,"shares_owned_after_display":"24,596.60","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-23","filed_date":"2012-02-24","scope":"insider"},{"id":2764917,"accession":"0001264124-12-000039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001264124-12-000039","line_url":"/filing/0001264124-12-000039#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (SVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (SVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3843.0,"shares_display":"3,843","price_per_share":16.6153,"price_display":"16.62","price_state":"stated","total_value":63852.5979,"total_display":"63,852.60","total_whole":"63,853","shares_owned_after":20415.6,"shares_owned_after_display":"20,415.60","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-08","filed_date":"2012-02-10","scope":"insider"},{"id":7167996,"accession":"0001454982-10-000099","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001454982-10-000099","line_url":"/filing/0001454982-10-000099#line-1","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001493811","owner_name":"Weyer Christian","owner_display_name":"Weyer Christian","owner_url":"/insider/0001493811","role":"Officer (SVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (SVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1314.0,"shares_display":"1,314","price_per_share":13.4204,"price_display":"13.42","price_state":"stated","total_value":17634.4056,"total_display":"17,634.41","total_whole":"17,634","shares_owned_after":3357.0,"shares_owned_after_display":"3,357","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-11-19","filed_date":"2010-11-19","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":17,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001270073","name":"INTERCEPT PHARMACEUTICALS, INC.","url":"/issuer/0001270073","role":"Officer (EVP, Research & Development)","n_filings":10,"first_seen":"2018-11-29","last_seen":"2020-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001434316","name":"FATE THERAPEUTICS INC","url":"/issuer/0001434316","role":"Director, Officer","n_filings":1,"first_seen":"2014-04-03","last_seen":"2014-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0000881464","name":"AMYLIN PHARMACEUTICALS INC","url":"/issuer/0000881464","role":"Officer (SVP, Research & Development), Other","n_filings":4,"first_seen":"2010-11-19","last_seen":"2012-03-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001493811","retrieved_at":"2026-08-25T01:22:35+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}